Abstract: Long non-coding RNAs (lncRNAs) play an indispensable role in the occurrence and development of ovarian cancer (OC). However, the potential involvement of lncRNAs in the progression of OC is largely unknown. To investigate the detailed roles and mechanisms of RAD51 homolog B-antisense 1 (RAD51B-AS1), a novel lncRNA in OC, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to verify the expression of RAD51B-AS1. Cellular proliferation, metastasis, and apoptosis were detected using the cell counting kit-8 (CCK-8), colony-formation, transwell, and flow cytometry assays. Mouse xenograft models were established for the detection of tumorigenesis. The results revealed that RAD51B-AS1 was significantly upregulated in a highly metastatic human OC cell line and OC tissues. RAD51B-AS1 significantly increased the proliferation and metastasis of OC cells and enhanced their resistance to anoikis. Biogenetics prediction analysis revealed that the only target gene of RAD51B-AS1 was RAD51B. Subsequent gene function experiments revealed that RAD51B exerts the same biological effects as RAD51B-AS1. Rescue experiments demonstrated that the malignant biological behaviors promoted by RAD51B-AS1 overexpression were partially or completely reversed by RAD51B silencing in vitro and in vivo. Thus, RAD51B-AS1 promotes the malignant biological behaviors of OC and activates the protein kinase B (Akt)/B cell lymphoma protein-2 (Bcl-2) signaling pathway, and these effects may be associated with the positive regulation of RAD51B expression. RAD51B-AS1 is expected to serve as a novel molecular biomarker for the diagnosis and prediction of poor prognosis in OC, and as a potential therapeutic target for disease management.

RAD51B-AS1通过上调RAD51B促进卵巢癌的恶性生物学行为

[1]BhanA, SoleimaniM, MandalSS, 2017. Long noncoding RNA and cancer: a new paradigm. Cancer Res, 77(15):3965-3981.

[2]ChenFF, ZhangL, WuJQ, et al., 2018. HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer. Cell Death Dis, 9(12):1176.

[3]ChenLM, YangPP, al HaqAT, et al., 2022. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. J Biomed Sci, 29:70.

[4]ChiuWC, FangPT, LeeYC, et al., 2020. DNA repair protein Rad51 induces tumor growth and metastasis in esophageal squamous cell carcinoma via a p38/Akt-dependent pathway. Ann Surg Oncol, 27(6):2090-2101.

[5]CruzC, Castroviejo-BermejoM, Gutiérrez-EnríquezS, et al., 2018. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol, 29(5):1203-1210.

[6]CuiXY, ZhanJK, LiuYS, 2021. Roles and functions of antisense lncRNA in vascular aging. Ageing Res Rev, 72:101480.

[7]DangW, CaoPF, YanQJ, et al., 2021. IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis. Cancer Lett, 523:135-147.

[8]DengSJ, ChenHY, ZengZ, et al., 2019. Nutrient stress-dysregulated antisense lncRNA GLS-AS impairs GLS-mediated metabolism and represses pancreatic cancer progression. Cancer Res, 79(7):1398-1412.

[9]D'YdewalleC, RamosDM, PylesNJ, et al., 2017. The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron, 93(1):66-79.

[10]EdiriweeraMK, TennekoonKH, SamarakoonSR, 2019. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol, 59:147-160.

[11]FaghihiMA, WahlestedtC, 2009. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol, 10(9):637-643.

[12]GibbonsHR, ShaginurovaG, KimLC, et al., 2018. Divergent lncRNA GATA3-AS1 regulates GATA3 transcription in T-helper 2 cells. Front Immunol, 9:2512.

[13]HuangJ, LuoHL, PanH, et al., 2018. Interaction between RAD51 and MCM complex is essential for RAD51 foci forming in colon cancer HCT116 cells. Biochemistry (Mosc), 83(1):69-75.

[14]JinLT, ChunJ, PanCY, et al., 2018. The PLAG1-GDH1 axis promotes anoikis resistance and tumor metastasis through CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell, 69(1):87-99.e7.

[15]KatayamaS, TomaruY, KasukawaT, et al., 2005. Antisense transcription in the mammalian transcriptome. Science, 309(5740):1564-1566.

[16]LheureuxS, GourleyC, VergoteI, et al., 2019. Epithelial ovarian cancer. Lancet, 393(10177):1240-1253.

[17]LiangHH, YuT, HanY, et al., 2018. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer, 17:119.

[18]LiuYJ, BurnessML, Martin-TrevinoR, et al., 2017. RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer. Clin Cancer Res, 23(2):514-522.

[19]NirmalaJG, LopusM, 2020. Cell death mechanisms in eukaryotes. Cell Biol Toxicol, 36(2):145-164.

[20]OudenaardenCRL, van de VenRAH, DerksenPWB, 2018. Re-inforcing the cell death army in the fight against breast cancer. J Cell Sci, 131(16):jcs212563.

[21]PanK, XieY, 2020. LncRNA FOXC2-AS1 enhances FOXC2 mRNA stability to promote colorectal cancer progression via activation of Ca²⁺-FAK signal pathway. Cell Death Dis, 11(6):434.

[22]PaoliP, GiannoniE, ChiarugiP, 2013. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta, 1833(12):3481-3498.

[23]PeiCL, GongXJ, ZhangY, 2020. LncRNA MALAT-1 promotes growth and metastasis of epithelial ovarian cancer via sponging microRNA-22. Am J Transl Res, 12(11):6977-6987.

[24]RevathideviS, MunirajanAK, 2019. Akt in cancer: mediator and more. Semin Cancer Biol, 59:80-91.

[25]ShenXM, WangCH, ZhuHH, et al., 2021. Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells. J Ovarian Res, 14:38.

[26]ShenZJ, GuLK, LiuYW, et al., 2022. PLAA suppresses ovarian cancer metastasis via METTL3-mediated m⁶A modification of TRPC3 mRNA. Oncogene, 41(35):4145-4158.

[27]StatelloL, GuoCJ, ChenLL, et al., 2021. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol, 22(2):96-118.

[28]SuWJ, XuM, ChenXQ, et al., 2017. Long noncoding RNA ZEB1-AS1 epigenetically regulates the expressions of ZEB1 and downstream molecules in prostate cancer. Mol Cancer, 16:142.

[29]SungH, FerlayJ, SiegelRL, et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209-249.

[30]TaferH, HofackerIL, 2008. RNAplex: a fast tool for RNA‍‒RNA interaction search. Bioinformatics, 24(22):2657-2663.

[31]TianH, LianR, LiY, et al., 2020. AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent vimentin degradation. Nat Commun, 11:5127.

[32]TorreLA, TrabertB, DesantisCE, et al., 2018. Ovarian cancer statistics, 2018. CA Cancer J Clin, 68(4):284-296.

[33]US Preventive Services Task Force, 2018. Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319(6):588-594.

[34]WangZY, JiaRX, WangLL, et al., 2022. The emerging roles of Rad51 in cancer and its potential as a therapeutic target. Front Oncol, 12:935593.

[35]WoditschkaS, EvansL, DuchnowskaR, et al., 2014. DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer. J Natl Cancer Inst, 106(7):dju145.

[36]WuDD, ChenX, SunKX, et al., 2017. Role of the lncRNA ABHD11-AS₁ in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer, 164:138.

[37]WuWM, GaoH, LiXF, et al., 2019. LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression. Cancer Sci, 110(5):1587-1598.

[38]WuYX, GuWQ, HanX, et al., 2021. LncRNA PVT1 promotes the progression of ovarian cancer by activating TGF‍-‍β pathway via miR-148a-3p/AGO1 axis. J Cell Mol Med, 25(17):8229-8243.

[39]XieWW, SunHZ, LiXD, et al., 2021. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int, 21:434.

[40]YangJ, PengSP, ZhangKQ, 2021. LncRNA RP11-499E18.1 inhibits proliferation, migration, and epithelial-mesenchymal transition process of ovarian cancer cells by dissociating PAK2-SOX2 interaction. Front Cell Dev Biol, 9:697831.

[41]ZhangCL, ZhuKP, MaXL, 2017. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett, 396:66-75.

[42]ZhangXM, MaNY, YaoWQ, et al., 2019. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Cancer Cell Int, 19:356.

[43]ZhaoL, JiangL, ZhangM, et al., 2021. NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay. Oncogene, 40(30):4919-4929.

[44]ZhouZZ, DengH, YanW, et al., 2014. AEG-1 promotes anoikis resistance and orientation chemotaxis in hepatocellular carcinoma cells. PLoS ONE, 9(6):e100372.